Preferred standard‐of‐care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists

Documenti analoghi

• Resumption of bone‐modifying agents in relapsed multiple myeloma does not improve outcomes: A real‐world analysis
  di: Malcolm Su, et al.
  Pubblicazione: (2026)
• Busulfan, melphalan and carfilzomib high‐dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma
  di: Patrick Hagen, et al.
  Pubblicazione: (2024)
• Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data
  di: Utkarsh Goel, et al.
  Pubblicazione: (2026)
• Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
  di: M. R. Seefat, et al.
  Pubblicazione: (2025)
• Outcomes of frail patients undergoing high‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma
  di: Stephanie Yohay, et al.
  Pubblicazione: (2024)